Search research articles
Contact Us
Filters
Showing results (811-820 of 824) with videos related to
Page
of 83
Sort By:
Journal of Medicinal Chemistry
|
July 28, 2023
Structure-Guided Design and Synthesis of a Pyridazinone Series of <i>Trypanosoma cruzi</i> Proteasome Inhibitors
Michael G Thomas, Kate McGonagle, Paul Rowland, et al.
Nature Medicine
|
July 4, 2018
Miscarriage and stillbirth following maternal Zika virus infection in nonhuman primates
Dawn M Dudley, Koen K Van Rompay, Lark L Coffey, et al.
Nature Communications
|
October 11, 2022
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs
Simon R Green, Susan H Davis, Sebastian Damerow, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
November 9, 2004
On the terminology for describing the length-force relationship and its changes in airway smooth muscle
Tony R Bai, Jason H T Bates, Vito Brusasco, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 10, 2019
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
Susan Wyllie, Stephen Brand, Michael Thomas, et al.
Nature Reviews. Chemistry
|
April 28, 2023
Towards the sustainable discovery and development of new antibiotics
Marcus Miethke, Marco Pieroni, Tilmann Weber, et al.
Nature Reviews. Chemistry
|
August 24, 2021
Towards the sustainable discovery and development of new antibiotics
Marcus Miethke, Marco Pieroni, Tilmann Weber, et al.
Research Square
|
December 9, 2024
Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining
Karla P Godinez-Macias, Daisy Chen, J Lincoln Wallis, et al.
NPJ Drug Discovery
|
March 11, 2025
Revisiting the <i>Plasmodium falciparum</i> druggable genome using predicted structures and data mining
Karla P Godinez-Macias, Daisy Chen, J Lincoln Wallis, et al.
Journal of Medicinal Chemistry
|
December 21, 2018
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis
Michael G Thomas, Manu De Rycker, Myriam Ajakane, et al.
Page
of 83
Search research articles
Search
Showing results (811-820 of 824) with videos related to
Sort By:
Page
of 83
Journal of Medicinal Chemistry
|
July 28, 2023
Structure-Guided Design and Synthesis of a Pyridazinone Series of <i>Trypanosoma cruzi</i> Proteasome Inhibitors
Michael G Thomas, Kate McGonagle, Paul Rowland, et al.
Nature Medicine
|
July 4, 2018
Miscarriage and stillbirth following maternal Zika virus infection in nonhuman primates
Dawn M Dudley, Koen K Van Rompay, Lark L Coffey, et al.
Nature Communications
|
October 11, 2022
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs
Simon R Green, Susan H Davis, Sebastian Damerow, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
November 9, 2004
On the terminology for describing the length-force relationship and its changes in airway smooth muscle
Tony R Bai, Jason H T Bates, Vito Brusasco, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 10, 2019
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
Susan Wyllie, Stephen Brand, Michael Thomas, et al.
Nature Reviews. Chemistry
|
April 28, 2023
Towards the sustainable discovery and development of new antibiotics
Marcus Miethke, Marco Pieroni, Tilmann Weber, et al.
Nature Reviews. Chemistry
|
August 24, 2021
Towards the sustainable discovery and development of new antibiotics
Marcus Miethke, Marco Pieroni, Tilmann Weber, et al.
Research Square
|
December 9, 2024
Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining
Karla P Godinez-Macias, Daisy Chen, J Lincoln Wallis, et al.
NPJ Drug Discovery
|
March 11, 2025
Revisiting the <i>Plasmodium falciparum</i> druggable genome using predicted structures and data mining
Karla P Godinez-Macias, Daisy Chen, J Lincoln Wallis, et al.
Journal of Medicinal Chemistry
|
December 21, 2018
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis
Michael G Thomas, Manu De Rycker, Myriam Ajakane, et al.
Page
of 83